{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:21:53Z","timestamp":1790619713252,"version":"4.1.0"},"reference-count":59,"publisher":"Impact Journals, LLC","issue":"51","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,12,20]]},"DOI":"10.18632\/oncotarget.12394","type":"journal-article","created":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T14:48:47Z","timestamp":1475333327000},"page":"84214-84227","source":"Crossref","is-referenced-by-count":29,"title":["Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia"],"prefix":"10.18632","volume":"7","author":[{"given":"Nameeta P.","family":"Richard","sequence":"first","affiliation":[{"name":"Randall Children's Hospital at Legacy Emanuel, Children's Cancer and Blood Disorders Program, Portland, OR USA-97227"},{"name":"Division of Pediatric Hematology Oncology, Oregon Health and Science University, Portland, OR, USA-97239"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Pippa","sequence":"additional","affiliation":[{"name":"Division of Oncology, Center for Applied Medical Research (CIMA), University of Navarra, Pio XII-55 Pamplona, Spain-31008"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan M.","family":"Cleary","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR, USA-97239"},{"name":"Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA-97239"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alka","family":"Puri","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR, USA-97239"},{"name":"Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA-97239"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanne","family":"Tibbitts","sequence":"additional","affiliation":[{"name":"Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, OR USA-97239"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Mahmood","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR, USA-97239"},{"name":"Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA-97239"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale J.","family":"Christensen","sequence":"additional","affiliation":[{"name":"Research and Development, Oncotide Pharmaceuticals, Research Triangle Park, NC USA 27710"},{"name":"Spyryx Biosciences, Durham, NC USA-27713"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Jeng","sequence":"additional","affiliation":[{"name":"Division of Bioinformatics and Computational Biology, Department of Medical Informatics and Clinical Epidemiology, Oregon Health and Science University, Portland, OR, 97239, USA"},{"name":"Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA-97239"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"McWeeney","sequence":"additional","affiliation":[{"name":"Division of Bioinformatics and Computational Biology, Department of Medical Informatics and Clinical Epidemiology, Oregon Health and Science University, Portland, OR, 97239, USA"},{"name":"Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA-97239"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Thomas","family":"Look","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Harvard Cancer Center, Boston, MA, USA 02215"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bill H.","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology Oncology, Oregon Health and Science University, Portland, OR, USA-97239"},{"name":"Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA-97239"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Tyner","sequence":"additional","affiliation":[{"name":"Department of Cell and Developmental Biology, Oregon Health and Science University, Portland, OR, USA-97239"},{"name":"Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA-97239"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Vitek","sequence":"additional","affiliation":[{"name":"Research and Development, Oncotide Pharmaceuticals, Research Triangle Park, NC USA 27710"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda D.","family":"Odero","sequence":"additional","affiliation":[{"name":"Division of Oncology, Center for Applied Medical Research (CIMA), University of Navarra, Pio XII-55 Pamplona, Spain-31008"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalie","family":"Sears","sequence":"additional","affiliation":[{"name":"Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, OR USA-97239"},{"name":"Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA-97239"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupriya","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR, USA-97239"},{"name":"Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, OR USA-97239"},{"name":"Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA-97239"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,10,1]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMra052603","article-title":"Treatment of Acute Lymphoblastic Leukemia","volume":"354","author":"Evans","year":"2006","journal-title":"NEJM"},{"key":"2","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1200\/JCO.2003.10.116","article-title":"Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience","volume":"21","author":"Asselin","year":"2003","journal-title":"JCO"},{"key":"3","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Powell","year":"2006","journal-title":"NEJM"},{"key":"4","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1172\/JCI61269","article-title":"The molecular basis of T cell acute lymphoblastic leukemia","volume":"122","author":"Ferrando","year":"2012","journal-title":"JCI"},{"key":"5","doi-asserted-by":"crossref","unstructured":"T-ALL pathogenesis requires a NOTCH1-driven MYC enhancer. Cancer Discov. 2014; 4:OF17.","DOI":"10.1158\/2159-8290.CD-RW2014-196"},{"key":"6","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrc1880","article-title":"Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia","volume":"6","author":"Look","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"7","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1182\/blood-2012-12-471904","article-title":"beta-Catenin activation synergizes with Pten loss and Myc overexpression in Notch-independent T-ALL","volume":"122","author":"Kirstetter","year":"2013","journal-title":"Blood"},{"key":"8","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1182\/blood-2013-08-522698","article-title":"c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells","volume":"123","author":"Kelliher","year":"2014","journal-title":"Blood"},{"key":"9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cellsig.2013.09.021","article-title":"New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of gamma-secretase inhibitor resistant T-cell acute lymphoblastic leukemia","volume":"26","author":"Matherly","year":"2014","journal-title":"Cell Signal"},{"key":"10","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/ncb1110","article-title":"A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells","volume":"6","author":"Means","year":"2004","journal-title":"Nat Cell Bioly"},{"key":"11","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1128\/MCB.26.7.2832-2844.2006","article-title":"Protein phosphatase 2A regulatory subunit B56alpha associates with c-myc and negatively regulates c-myc accumulation","volume":"26","author":"Sears","year":"2006","journal-title":"MCB"},{"key":"12","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1158\/1078-0432.CCR-14-0166","article-title":"SETting OP449 into the PP2A-activating drug family","volume":"20","author":"Perrotti","year":"2014","journal-title":"Clin Canc Res"},{"key":"13","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1042\/bj3530417","article-title":"Protein phosphatase 2A: a highly regulated family of serine\/threonine phosphatases implicated in cell growth and signalling","volume":"353","author":"Goris","year":"2001","journal-title":"Biochem J"},{"key":"14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10555-008-9119-x","article-title":"Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias","volume":"27","author":"Neviani","year":"2008","journal-title":"Cancer Metast Rev"},{"key":"15","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/leu.2010.294","article-title":"PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect","volume":"25","author":"Odero","year":"2011","journal-title":"Leukemia"},{"key":"16","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3324\/haematol.2011.050542","article-title":"Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia","volume":"97","author":"Odero","year":"2012","journal-title":"Haematologica"},{"key":"17","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1172\/JCI31095","article-title":"FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia","volume":"117","author":"Marcucci","year":"2007","journal-title":"JCI"},{"key":"18","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccr.2005.10.015","article-title":"The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR\/ABL-regulated SET protein","volume":"8","author":"Bruner-Klisovic","year":"2005","journal-title":"Cancer Cell"},{"key":"19","doi-asserted-by":"crossref","first-page":"5438","DOI":"10.1158\/0008-5472.CAN-09-2544","article-title":"Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers","volume":"70","author":"Verrills","year":"2010","journal-title":"Cancer Res"},{"key":"20","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1038\/onc.2009.7","article-title":"Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients","volume":"28","author":"Arlinghaus","year":"2009","journal-title":"Oncogene"},{"key":"21","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1038\/onc.2010.622","article-title":"Targeting SET\/IPP2A oncoprotein functions as a multi-pathway strategy for cancer therapy","volume":"30","author":"Vitek","year":"2011","journal-title":"Oncogene"},{"key":"22","first-page":"1314","article-title":"Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation","volume":"113","author":"Huang","year":"2012","journal-title":"JCB"},{"key":"23","first-page":"6","article-title":"Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer","volume":"111","author":"Sears","year":"2014","journal-title":"PNAS"},{"key":"24","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1016\/S1470-2045(12)70558-2","article-title":"Protein phosphatase 2A: a target for anticancer therapy","volume":"14","author":"Neviani","year":"2013","journal-title":"Lancet Oncol"},{"key":"25","first-page":"78","article-title":"Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia","volume":"6","author":"Odero","year":"2016","journal-title":"Front Oncol"},{"key":"26","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood-2009-06-227363","article-title":"SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia","volume":"115","author":"Odero","year":"2010","journal-title":"Blood"},{"key":"27","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1158\/1078-0432.CCR-14-0724","article-title":"Deregulation of the PP2A inhibitor SET shows promising therapeutic implications and determines poor clinical outcome in patients with metastatic colorectal cancer","volume":"21","author":"Garcia-Foncillas","year":"2015","journal-title":"Clin Cancer Res"},{"key":"28","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.3892\/ol.2014.1866","article-title":"Involvement of SET in the Wnt signaling pathway and the development of human colorectal cancer","volume":"7","author":"Chen","year":"2014","journal-title":"Oncol Lett"},{"key":"29","doi-asserted-by":"crossref","first-page":"15182","DOI":"10.1038\/srep15182","article-title":"Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis","volume":"5","author":"Mulholland","year":"2015","journal-title":"Sci Rep"},{"key":"30","doi-asserted-by":"publisher","first-page":"638","DOI":"10.18632\/oncotarget.6313","article-title":"SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"key":"31","doi-asserted-by":"publisher","first-page":"14913","DOI":"10.18632\/oncotarget.3818","article-title":"Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer","volume":"6","author":"He","year":"2015","journal-title":"Oncotarget"},{"key":"32","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1182\/blood-2011-04-351072","article-title":"SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target","volume":"118","author":"de Castro","year":"2011","journal-title":"Blood"},{"key":"33","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.4049\/jimmunol.1002847","article-title":"Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A","volume":"186","author":"Vitek","year":"2011","journal-title":"J Immunol"},{"key":"34","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1158\/1078-0432.CCR-13-2575","article-title":"Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia","volume":"20","author":"Druker","year":"2014","journal-title":"Clin Cancer Res"},{"key":"35","doi-asserted-by":"crossref","first-page":"e0161158","DOI":"10.1371\/journal.pone.0161158","article-title":"IGF1R Derived PI3K\/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias","volume":"11","author":"Weng","year":"2016","journal-title":"PloS one"},{"key":"36","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1158\/2159-8290.CD-12-0504","article-title":"TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia","volume":"3","author":"Ahn","year":"2013","journal-title":"Cancer Discov"},{"key":"37","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1016\/j.celrep.2015.02.056","article-title":"FAK mediates a compensatory survival signal parallel to PI3K-AKT in PTEN-null T-ALL cells","volume":"10","author":"Zeleznik-Le","year":"2015","journal-title":"Cell rep"},{"key":"38","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cell.2007.04.044","article-title":"CIP2A inhibits PP2A in human malignancies","volume":"130","author":"Chan","year":"2007","journal-title":"Cell"},{"key":"39","doi-asserted-by":"crossref","unstructured":"Pippa, Dominguez, Malumbres, Endo, Arriazu, Marcotegui, Guruceaga, Odero. MYC-dependent recruitment of RUNX1 and GATA2 on the SET oncogene promoter enhances PP2A inactivation in acute myeloid leukemia. Oncotarget. 2016 Jun 6. https:\/\/doi.org\/10.18632\/oncotarget.9840. [Epub ahead of print].","DOI":"10.18632\/oncotarget.9840"},{"key":"40","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1158\/0008-5472.CAN-08-4295","article-title":"Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells","volume":"69","author":"Draetta","year":"2009","journal-title":"Cancer Res"},{"key":"41","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/leu.2012.285","article-title":"PI3K\/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response","volume":"27","author":"Khwaja","year":"2013","journal-title":"Leukemia"},{"key":"42","doi-asserted-by":"crossref","first-page":"9085","DOI":"10.1073\/pnas.0402770101","article-title":"The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation","volume":"101","author":"Clurman","year":"2004","journal-title":"PANS"},{"key":"43","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1053\/j.seminoncol.2006.04.005","article-title":"New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors","volume":"33","author":"Raymond","year":"2006","journal-title":"Semin Oncol"},{"key":"44","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s12094-006-0005-0","article-title":"Protein kinases and phosphatases as therapeutic targets in cancer","volume":"8","author":"Nebreda","year":"2006","journal-title":"Clin Transl Oncol"},{"key":"45","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1158\/0008-5472.CAN-12-1906","article-title":"Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening","volume":"73","author":"Gotlib","year":"2013","journal-title":"Cancer Res"},{"key":"46","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2217\/fon.14.208","article-title":"Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity","volume":"11","author":"Paglino","year":"2015","journal-title":"Future Oncol"},{"key":"47","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/ejh.12491","article-title":"Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation","volume":"95","author":"Stewart","year":"2015","journal-title":"Eur J Haematol"},{"key":"48","doi-asserted-by":"crossref","first-page":"7451","DOI":"10.1158\/1078-0432.CCR-11-1747","article-title":"Phase I\/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma","volume":"17","author":"Kirkwood","year":"2011","journal-title":"Clin Cancer Res"},{"key":"49","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1128\/MCB.01455-12","article-title":"Pin1 regulates the dynamics of c-Myc DNA binding to facilitate target gene regulation and oncogenesis","volume":"33","author":"Sears","year":"2013","journal-title":"MCB"},{"key":"50","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.3324\/haematol.2014.115691","article-title":"c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia","volume":"100","author":"Clark","year":"2015","journal-title":"Haematologica"},{"key":"51","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group","volume":"30","author":"Carroll","year":"2012","journal-title":"JOC"},{"key":"52","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.1102160","article-title":"Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia","volume":"306","author":"Aster","year":"2004","journal-title":"Science"},{"key":"53","first-page":"353","article-title":"The role of NOTCH1 signaling in T-ALL","volume":"2009","author":"Ferrando","year":"2009","journal-title":"ASH Education Program Book"},{"key":"54","doi-asserted-by":"crossref","first-page":"6650","DOI":"10.1182\/blood-2011-02-336842","article-title":"Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia","volume":"117","author":"Morgado","year":"2011","journal-title":"Blood"},{"key":"55","doi-asserted-by":"crossref","first-page":"5651","DOI":"10.1038\/srep05651","article-title":"Andrographolide induces vascular smooth muscle cell apoptosis through a SHP-1-PP2A-p38MAPK-p53 cascade","volume":"4","author":"Sheu","year":"2014","journal-title":"Sci Rep"},{"key":"56","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1084\/jem.20070876","article-title":"FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors","volume":"204","author":"Clurman","year":"2007","journal-title":"JEM"},{"key":"57","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1172\/JCI65093","article-title":"Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia","volume":"124","author":"Clemons","year":"2014","journal-title":"JCI"},{"key":"58","unstructured":"Lou. Dual: Multi-Pronged Attack. Biocentury. 2014. 6-23\u201314:1."},{"key":"59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1476-5586(04)80047-2","article-title":"ONCOMINE: a cancer microarray database and integrated data-mining platform","volume":"6","author":"Chinnaiyan","year":"2004","journal-title":"Neoplasia"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.12394","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T09:12:21Z","timestamp":1692522741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.12394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,1]]},"references-count":59,"journal-issue":{"issue":"51","published-print":{"date-parts":[[2016,12,20]]}},"alternative-id":["12394","27705940"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.12394","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,1]]}}}